Effect of omeprazole on platelet reactivity in patients with diabetes mellitus and coronary artery disease receiving aspirin and clopidogrel: a randomised, placebo-controlled crossover trial (POC-DM)
4 affiliations
- 1Cardiovascular Unit, Mahidol University Faculty of Medicine Ramathibodi Hospital Department of Medicine, Bangkok, Thailand
- 2Anatomical Pathology Unit, Division of Pathology, Prince of Songkla University Faculty of Medicine, Hat Yai, Thailand
- 3Department of Pharmacy, Mahidol University Ramathibodi Hospital, Bangkok, Thailand
- 4Division of Cardiology, Mahidol University Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand
Abstract
Background: Proton pump inhibitors are often prescribed with aspirin and clopidogrel to reduce gastrointestinal bleeding risk. However, the European Society of Cardiology diabetes guidelines recommend avoiding concomitant use of omeprazole and clopidogrel due to potential drug–drug interactions. Evidence in patients with diabetes mellitus (DM), who have a higher prevalence of high on-treatment platelet reactivity, remains limited. In Thailand, where omeprazole is the only reimbursed PPI, this potential interaction has important clinical implications. We aimed to evaluate the effect of omeprazole on platelet reactivity, measured as P2Y12 reaction units (PRU), in patients with DM and coronary artery disease (CAD) receiving aspirin and clopidogrel.
Methods: This double-blind, randomised, placebo-controlled crossover trial enrolled patients with DM and CAD receiving aspirin 81 mg/day and clopidogrel 75 mg/day. Participants received omeprazole 20 mg or a matching placebo for 2 weeks, followed by crossover to the alternate treatment. Platelet reactivity was assessed using the VerifyNow P2Y12 assay. The primary outcome was the change in PRU following omeprazole coadministration compared with both baseline and placebo. Secondary outcomes included changes in clopidogrel responder status (PRU >208) before and after omeprazole treatment and PRU values in each treatment period.
Results: 50 patients were enrolled (median age 67 years; 58% male). Omeprazole significantly increased PRU by a mean difference of 20.57 units versus baseline (p=0.002) and 16.14 units versus placebo (p=0.006). The proportion of clopidogrel non-responders increased from 44% to 56%, with 25% of baseline responders converting to non-responders.
Conclusions: Omeprazole significantly attenuated clopidogrel’s antiplatelet effect in patients with diabetes and CAD. Concomitant use may be avoided, especially in those with high thrombotic risk.
Trial registration number: TCTR20260714003.
Related
- Photobiomodulation therapy combined with a static magnetic field in critically ill patients receiving invasive mechanical ventilation: protocol for a multicentre randomised triple-blind placebo-controlled trial.
- Effect of dapagliflozin on renal response in patients with biopsy-confirmed lupus nephritis receiving stable maintenance immunosuppression and renin–angiotensin system inhibition: protocol for the multicentre randomised DAPA-LN trial
- Acupuncture for older adults with dementia in residential care homes: an assessor-blinded, randomised controlled trial
- Standardised procalcitonin monitoring and antibiotic duration in community-acquired sepsis: a pragmatic randomised controlled trial
- Efficacy and Safety of a Novel Oil Pulling Oral Rinse for Teeth Whitening: A Double-Blind, Randomised, Placebo-Controlled Trial
BibTeX
@article{thungthienthong2026effect,
title = {{Effect of omeprazole on platelet reactivity in patients with diabetes mellitus and coronary artery disease receiving aspirin and clopidogrel: a randomised, placebo-controlled crossover trial (POC-DM)}},
author = {Metus Thungthienthong and Salisa Kluntang and Wannakorn Khopanlert and Pitchapa Kaewkan and Krissada Meemook and Kanchit Likittanasombut and Pakorn Chandanamattha and Prin Vathesatogkit},
journal = {Open Heart},
year = {2026},
month = nov,
doi = {10.1136/openhrt-2026-004409},
url = {https://doi.org/10.1136/openhrt-2026-004409},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Effect of omeprazole on platelet reactivity in patients with diabetes mellitus and coronary artery disease receiving aspirin and clopidogrel: a randomised, placebo-controlled crossover trial (POC-DM)
AU - Metus Thungthienthong
AU - Salisa Kluntang
AU - Wannakorn Khopanlert
AU - Pitchapa Kaewkan
AU - Krissada Meemook
AU - Kanchit Likittanasombut
AU - Pakorn Chandanamattha
AU - Prin Vathesatogkit
PY - 2026
DA - 2026/11/02
JO - Open Heart
DO - 10.1136/openhrt-2026-004409
UR - https://doi.org/10.1136/openhrt-2026-004409
AB - Background: Proton pump inhibitors are often prescribed with aspirin and clopidogrel to reduce gastrointestinal bleeding risk. However, the European Society of Cardiology diabetes guidelines recommend avoiding concomitant use of omeprazole and clopidogrel due to potential drug–drug interactions. Evidence in patients with diabetes mellitus (DM), who have a higher prevalence of high on-treatment platelet reactivity, remains limited. In Thailand, where omeprazole is the only reimbursed PPI, this potential interaction has important clinical implications. We aimed to evaluate the effect of omeprazole on platelet reactivity, measured as P2Y12 reaction units (PRU), in patients with DM and coronary artery disease (CAD) receiving aspirin and clopidogrel. Methods: This double-blind, randomised, placebo-controlled crossover trial enrolled patients with DM and CAD receiving aspirin 81 mg/day and clopidogrel 75 mg/day. Participants received omeprazole 20 mg or a matching placebo for 2 weeks, followed by crossover to the alternate treatment. Platelet reactivity was assessed using the VerifyNow P2Y12 assay. The primary outcome was the change in PRU following omeprazole coadministration compared with both baseline and placebo. Secondary outcomes included changes in clopidogrel responder status (PRU >208) before and after omeprazole treatment and PRU values in each treatment period. Results: 50 patients were enrolled (median age 67 years; 58% male). Omeprazole significantly increased PRU by a mean difference of 20.57 units versus baseline (p=0.002) and 16.14 units versus placebo (p=0.006). The proportion of clopidogrel non-responders increased from 44% to 56%, with 25% of baseline responders converting to non-responders. Conclusions: Omeprazole significantly attenuated clopidogrel’s antiplatelet effect in patients with diabetes and CAD. Concomitant use may be avoided, especially in those with high thrombotic risk. Trial registration number: TCTR20260714003.
SN - 2053-3624
ER -